KAMADA LTD. Inactive Instrument
Kamada Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
KMDA
IL0010941198
Pharmaceuticals
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 587M 158M 216M | Sales 2025 * | 664M 179M 244M | Capitalization | 1.2B 322M 440M |
|---|---|---|---|---|---|
| Net income 2024 * | 55M 14.8M 20.21M | Net income 2025 * | 66M 17.76M 24.25M | EV / Sales 2024 * | 2.04 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.8 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kamada Ltd.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 55 | 13-12-08 |
David Tsur
FOU | Founder | 73 | 90-12-12 |
Chaime Orlev
DFI | Director of Finance/CFO | 53 | 17-12-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 19-12-23 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
David Tsur
FOU | Founder | 73 | 90-12-12 |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
